FibroBiologics to Present Corporate Update at 2023 BIO International Convention
Clinical-Stage Company Focused on Advancing Fibroblast Cell-Based Therapies for Treatment of Chronic Diseases HOUSTON, June 1, 2023 /PRNewswire/ — FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today announced that Pete O’Heeron, Founder and Chief Executive Officer, will present a corporate overview next week at the 2023 BIO International … Read more